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The	polycomb	group	protein	B	lymphoma	Mo-MLV	insertion	region	1	homolog	(Bmi-1)	is	dysregulated	in	
various	cancers,	and	its	upregulation	strongly	correlates	with	an	invasive	phenotype	and	poor	prognosis	in	
patients	with	nasopharyngeal	carcinomas.	However,	the	underlying	mechanism	of	Bmi-1–mediated	inva-
siveness	remains	unknown.	In	the	current	study,	we	found	that	upregulation	of	Bmi-1	induced	epithelial-
mesenchymal	transition	(EMT)	and	enhanced	the	motility	and	invasiveness	of	human	nasopharyngeal	epithe-
lial	cells,	whereas	silencing	endogenous	Bmi-1	expression	reversed	EMT	and	reduced	motility.	Furthermore,	
upregulation	of	Bmi-1	led	to	the	stabilization	of	Snail,	a	transcriptional	repressor	associated	with	EMT,	via	
modulation	of	PI3K/Akt/GSK-3β	signaling.	Chromatin	immunoprecipitation	assays	revealed	that	Bmi-1	tran-
scriptionally	downregulated	expression	of	the	tumor	suppressor	PTEN	in	tumor	cells	through	direct	associa-
tion	with	the	PTEN	locus.	This	in	vitro	analysis	was	consistent	with	the	statistical	inverse	correlation	detected	
between	Bmi-1	and	PTEN	expression	in	a	cohort	of	human	nasopharyngeal	carcinoma	biopsies.	Moreover,	
ablation	of	PTEN	expression	partially	rescued	the	migratory/invasive	phenotype	of	Bmi-1–silenced	cells,	indi-
cating	that	PTEN	might	be	a	major	mediator	of	Bmi-1–induced	EMT.	Our	results	provide	functional	and	
mechanistic	links	between	the	oncoprotein	Bmi-1	and	the	tumor	suppressor	PTEN	in	the	development	and	
progression	of	cancer.
Introduction
Polycomb group (PcG) proteins are epigenetic gene-silencing 
proteins that have been implicated in embryonic development 
and oncogenesis (1–4). Numerous studies have shown that PcG 
proteins are frequently dysregulated in various cancer types 
and strongly correlate with an invasive or metastatic phenotype 
(5–10). PcG protein B lymphoma Mo-MLV insertion region 1 
homolog (Bmi-1), the first functionally identified PcG member, 
was originally identified as an oncogene cooperating with c-Myc 
in a murine lymphomagenesis model (11, 12). In humans, Bmi-1 
plays an essential role in maintaining the self-renewal of normal 
and malignant human mammary stem cells (13). Meanwhile, Bmi-1 
is also dysregulated in various human malignant neoplasms 
(14–19). Previously, we reported that upregulation of Bmi-1 cor-
relates with invasion of nasopharyngeal carcinomas (NPCs) and 
poor prognosis in patients (20). A possible mechanism of tumori-
genesis involves repression of the Ink4a-Arf locus, which encodes 
the tumor suppressors INK4A and ARF (21), by direct binding of 
Bmi-1. However, Bmi-1 is also required for tumor development 
in an orthotopic transplantation model for glioma independent 
of Ink4a/Arf (22). Although the molecular mechanism of PcG in 
mammalian embryonic development and decisions of cell fate 
has been thoroughly elucidated by the identification of multiple 
potential PcG-targeted genes via genome-wide ChIP-on-chip 
analyses (23–25), the precise role of Bmi-1 in cancer invasion and 
metastasis remains largely unknown.
Epithelial-mesenchymal transition (EMT) is known to be a 
central mechanism responsible for invasiveness and metastasis 
of various cancers (26, 27). A key step in EMT is downregulation 
of E-cadherin (28, 29). Snail-related zinc-finger transcriptional 
repressors (Snail and Slug) (30, 31), the repressor SIP-1/ZEB-2 
(32), ΔEF-1/ZEB-1 (33), as well as bHLH transcription factors 
Twist (34) and E12/E47 (29, 35) are the most prominent suppres-
sors of E-cadherin transcription; these proteins act by binding to 
specific E-boxes in the E-cadherin promoter. Recently, modifica-
tion of chromatin structure within the E-cadherin promoter was 
shown to correlate with EMT (36). It has been reported that EZH2 
mediates transcriptional silencing of the tumor suppressor gene 
E-cadherin by trimethylation of the H3 lysine 27 (37).
Herein, we demonstrate that ectopic expression of Bmi-1 in nor-
mal nasopharyngeal epithelial cells (NPECs) is sufficient to cause 
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EMT, while knockdown of Bmi-1 in NPC cells reduces cell inva-
sion. Most importantly, we show that PTEN is a direct target of 
Bmi-1. Bmi-1 binds to the PTEN locus and downregulates PTEN 
expression, which consequently activates the PI3K/Akt pathway, 
stabilizes Snail, and downregulates E-cadherin, ultimately leading 
to enhanced invasiveness of epithelial cells. Taken together, our 
results provide an explanation for the aggressive nature of human 
tumors overexpressing Bmi-1 and the mechanism that links Bmi-1 
to the key tumor suppressor PTEN.
Results
Ectopic expression of Bmi-1 induces EMT and enhances the invasiveness of 
NPECs in vitro. Previously we reported that upregulation of Bmi-1 
induces immortalization of NPECs (20). Meanwhile, a dramatic mor-
phological change was observed in Bmi-1–induced immortalized 
NPECs, in which the typical cobblestone-like appearance of normal 
epithelium was replaced by a spindle-like, fibroblastic morphology 
(Figure 1A), which suggested that Bmi-1/NPECs might have under-
gone EMT. In order to determine whether Bmi-1 induces EMT, we 
probed the cells with epithelial and mesenchymal markers. As shown 
in Figure 1B, Bmi-1/NPECs exhibited the typical EMT phenotype, 
including downregulation of epithelial markers E-cadherin and 
α-catenin and upregulation of mesenchymal markers fibronectin 
and vimentin. The EMT phenotype was confirmed by immunofluo-
rescent staining (Figure 1C). The same phenomena were observed in 
Madin-Darby canine kidney (MDCK) cells transduced with Bmi-1 
(Supplemental Figures 1 and 2; supplemental material available 
online with this article; doi:10.1172/JCI39374DS1).
Cancer progression is aided when EMT augments tumor cell 
motility and consequent invasion into the basement membrane 
leading to advanced metastasis. Thus, we investigated the effect of 
Bmi-1 on cell invasion and motility by conducting assays for Matri-
gel-coated Boyden chamber invasion and wound healing. As shown 
in Figure 1D, Bmi-1/NPECs displayed significantly increased inva-
siveness in comparison with vector control cells. A scratch wound-
healing assay also indicated that NPECs overexpressing Bmi-1 
exhibited significantly enhanced mobility compared with vector 
control cells (Supplemental Figure 3). The invasive and migratory 
phenotype dependent on overexpression of Bmi-1 was also observed 
in MDCK cells (Supplemental Figure 4). Taken together, our results 
suggest that upregulation of Bmi-1 is sufficient to induce EMT and 
enhance invasiveness of NPECs in vitro.
Silencing endogenous Bmi-1 represses the EMT phenotype and reduces 
transformation and metastatic potential of NPC cells. To further investi-
gate the impact of Bmi-1 on EMT, we silenced endogenous Bmi-1 
in CNE2 and HONE-1 NPC cells using specific shRNAs and exam-
ined the resulting phenotype. Both shRNAs specifically knocked 
down endogenous Bmi-1 protein in both NPC cell lines. shRNA #2 
was more efficient, and was therefore chosen for subsequent stud-
ies (Figure 2A). As shown in Figure 2, A and B, silencing endog-
enous Bmi-1 in NPC cells led to enhanced expression of epithelial 
markers and concomitant decreased expression of mesenchymal 
markers. Matrigel invasion chamber assays revealed that ablation 
of endogenous Bmi-1 markedly reduced invasiveness of NPC cell 
lines CNE2 and HONE-1 (Figure 2B). We next examined the effect 
of Bmi-1 on the tumorigenic activity of NPC cells using an anchor-
age-independent growth assay. As shown in Figure 2C, depletion of 
endogenous Bmi-1 in CNE2 and HONE-1 cells caused significant 
inhibition of their anchorage-independent growth, as indicated by 
reduction in colony number and colony size on soft agar (P < 0.01). 
Therefore, we determined that Bmi-1 is essential for malignant 
transformation of NPC cells.
We next evaluated in vivo effects of Bmi-1 depletion on invasion 
and metastasis using an experimental metastasis assay in which 
we injected CNE2 cells producing shRNA #2 against Bmi-1 or con-
trol shRNA into the lateral tail vein of 6-week-old nude mice and 
evaluated cell growth in the lung. Control shRNA cells formed 8 to 
40 metastatic nodules per lung in all 7 mice analyzed, which were 
evaluated under a dissection microscope. In contrast, 7 nude mice 
injected with cells expressing shRNA #2 against Bmi-1 formed 0 to 
6 nodules per lung (Figure 2D). H&E staining confirmed that both 
the number and the volume of micrometastatic lesions were mark-
edly reduced in the lungs of mice injected with shRNA #2 (Figure 
2E). Our data indicate that Bmi-1 is necessary for the aggressive 
metastatic phenotype of CNE2 cells.
Upregulation of Bmi-1 activates the PI3K/Akt/GSK-3β pathway. Our 
recent study suggested that Bmi-1 could modulate Akt activity in 
breast cancer cells in a p16INK4A-independent manner (38). Because 
activation of the PI3K/Akt pathway is emerging as a central feature 
of EMT (26, 39–42), we asked whether Bmi-1 regulates Akt activ-
ity in NPC cells. As shown in Figure 3A, upregulation of Bmi-1 did 
indeed facilitate phosphorylation of Akt in both NPEC1 and NPEC2 
cells, whereas Akt phosphorylation was inhibited in cells transduced 
with siRNA against Bmi-1. The increase in Akt phosphorylation was 
accompanied by a change in phosphorylation of GSK-3β, a down-
stream target protein of Akt, suggesting that upregulation of Bmi-1 
activates the Akt/GSK-3β pathway in NPC cells.
Previously, GSK-3β activity was demonstrated to be necessary 
for the maintenance of epithelial architecture by dual regulation 
of Snail (43, 44). As shown in Figure 3A, Western blotting revealed 
that, compared with vector cells, expression of Snail significantly 
increased in Bmi-1/NPECs but decreased in shRNA/NPC cells (Fig-
ure 3A). However, real-time RT-PCR shows no significant change 
in Snail mRNA (L.-B. Song, unpublished observations), suggesting 
that modulation of Snail expression might be due to posttrans-
lational modification. We next examined the half-life of Snail in 
Bmi-1/NPEC1 and vector/NPEC1 cells. The half-life of Snail was 
determined to be approximately 25 minutes in vector/NPEC1 cells, 
which is consistent with a previous report (44). However, its half-life 
dramatically increased to more than 90 minutes in Bmi-1/NPEC1 
cells (Figure 3B). On the other hand, shRNA #2 expression reduced 
the half-life of Snail protein from approximately 120 minutes to less 
than 60 minutes in CNE2 cells (Figure 3B). Immunofluorescence 
staining confirmed the supposition that the extension of the half-
life of Snail was primarily due to its subcellular localization, which 
is regulated by GSK-3β (44, 45). As shown in Figure 3C, Snail local-
ized to both the nucleus and cytoplasm in Vector/NPECs, whereas 
it was mainly detected in the nucleus of Bmi-1/NPECs. In con-
trol CNE2 and HONE-1 cells, Snail was primarily nuclear, but its 
expression decreased markedly as it translocated to the cytoplasm 
following knockdown of Bmi-1 (Figure 3C).
In addition, several kinase inhibitors, including wortmannin 
(PI3K inhibitor), U0126 (MEK inhibitor), and PD98059 (MAPK 
inhibitor), were used to investigate whether the stabilization of 
Snail was caused by activation of PI3K/Akt/GSK-3β pathway. Sup-
plemental Figure 5 shows that expression of phosphorylated Akt 
was reduced by wortmannin treatment, leading to further reduc-
tion of phosphorylated GSK-3β and Snail. However, no obvious 
alterations to phosphorylated GSK-3β or Snail were found in cells 
treated with MAPK (PD98059) or MEK (UO126) inhibitors.
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Figure 1
Overexpression of the Bmi-1 gene induces EMT in NPEC cells. (A) Morphology of NPEC1 and NPEC2 expressing either the control vector 
pMSCV or pMSCV/Bmi-1 are shown by phase contrast. Original magnification, ×400. (B) Expression of the epithelial proteins E-cadherin and 
α-catenin and the mesenchymal proteins fibronectin and vimentin in NPEC1 and NPEC2 cells expressing control vector pMSCV or pMSCV/Bmi-1 
were detected by Western blot. α-Tubulin was used as a loading control. (C) NPEC1 and NPEC2 cells expressing control vector pMSCV or 
pMSCV/Bmi-1 were replated on 10% fetal bovine serum/RPMI-1640–precoated coverslips. After an additional 24 hours, cells were stained for 
E-cadherin, α-catenin, fibronectin, vimentin, and DAPI and analyzed by confocal microscopy. The green signal represents staining for the cor-
responding protein, while the red signal signifies nuclear DNA staining with rhodamine. Scale bar: 80 μm. (D) The invasive properties of the cells 
were analyzed in by an invasion assay using a Matrigel-coated Boyden chamber. Migrated cells were plotted as the average number of cells per 
field of view from 3 different experiments, as described in Methods. Original magnification, ×400. Error bars represent SEM. **P < 0.01.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 12   December 2009 3629
Snail is required for Bmi-1–mediated E-cadherin downregulation. We 
utilized real-time PCR to investigate whether Snail is involved in 
Bmi-1–induced E-cadherin downregulation at the mRNA level. As 
shown in Figure 3D, the level of E-cadherin mRNA was signifi-
cantly reduced in Bmi-1/NPECs compared with control cells (Fig-
ure 3D). Luciferase reporter assays indicated that downregulation 
of E-cadherin was achieved through suppression of E-cadherin 
promoter activity (Figure 3E). Moreover, E-cadherin expression 
could be rescued by silencing Snail in Bmi-1/NPECs, and ectopic 
expression of Snail blocked upregulation of E-cadherin in Bmi-1 
shRNA/NPC cells (Figure 3F).
Because it has been reported that PRC2 represses E-cadherin 
transcription by binding to its promoter in a Snail-dependent 
manner (45), we examined whether Bmi-1 associates with the 
E-cadherin promoter. ChIP assays revealed that Bmi-1 was able 
to bind the E-cadherin promoter. Furthermore, the interaction 
was compromised when Snail was silenced (Figure 3G), suggest-
ing that the transcriptional regulation by Bmi-1 of E-cadherin 
Figure 2
Suppression of endogenous Bmi-1 expression in NPC cells reverses EMT and transformation in vitro and reduces metastasis in vivo. (A) Expres-
sion of the indicated proteins was analyzed by Western blot. (B) The invasive properties of Bmi-1 shRNA– (shRNA #2) or scrambled shRNA–
expressing NPC cell lines were analyzed in an invasion assay using a Matrigel-coated Boyden chamber as described in Figure 1D. Original 
magnification, ×400. Error bars represent SEM. *P < 0.05. (C) Anchorage-independent growth of Bmi-1 shRNA or scrambled shRNA cells in soft 
agar. Original magnification, ×400. Error bars represent SEM. *P < 0.05; **P < 0.01. (D) Number of metastases in lungs of mice (n = 7 per group) 
8 weeks after tail vein injection of scrambled control shRNA (blue; mean ± SEM, 17.6 ± 11.0) and Bmi-1 shRNA CNE2 cells (yellow; mean ± SEM, 
2.8 ± 2.5). The nodules were examined under an anatomical microscope. (E) Left: Representative lungs stained with trinitrophenol. Arrowheads 
indicate the metastatic nodes. Right: Representative H&E staining of lung metastatic tumors is shown. Original magnification, ×200.
research article
3630	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 12   December 2009
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 12   December 2009 3631
requires Snail. Taken together, our results indicate that Snail plays 
an important role in Bmi-1 regulation of E-cadherin.
Bmi-1 represses the tumor suppressor PTEN by associating at the PTEN 
locus. As a transcriptional repressor, Bmi-1 is unable to activate the 
PI3K/Akt pathway directly. We speculated that Bmi-1–dependent 
activation of the PI3K/Akt pathway was due to transcriptional 
repression of an Akt-negative regulator by Bmi-1. It is well known 
that the tumor suppressor PTEN negatively regulates the PI3K/Akt 
pathway (46). Therefore, the expression of PTEN was examined in 
Bmi-1–infected as well as Bmi-1 shRNA–infected and control vec-
tor–infected cells. As shown in Figure 4A, expression of PTEN was 
lower in Bmi-1/NPECs than in vector control cells, whereas silenc-
ing Bmi-1 upregulated PTEN expression in CNE2 and HONE-1 
NPC cells (Figure 4A). Real-time RT-PCR analysis revealed that over-
expression of Bmi-1 resulted in downregulation of PTEN mRNA, 
while downregulation of Bmi-1 led to an increase in the PTEN 
mRNA level (Figure 4A). These results were confirmed by transiently 
transfecting Cos-7 cells with a Bmi-1 expression vector to reduce 
endogenous expression of PTEN in a dose-dependent manner (Fig-
ure 4B). ChIP assays were performed to investigate whether Bmi-1 
associates with the PTEN locus. As shown in Figure 4, C and D, 
Bmi-1 binds to the region of the PTEN promoter from –0.9 kb to 
–2.3 kb and from 0.4 kb to 1.4 kb; the p16INK4A and GAPDH loci 
were used as positive and negative controls, respectively. In addi-
tion, Bmi-1 bound to the PTEN promoter much less efficiently in 
Bmi-1 shRNA/CNE2 cells (Figure 4E), indicating that the associa-
tion was specific. All of the results mentioned above demonstrate 
that Bmi-1 can transcriptionally repress PTEN expression.
It has been reported that Bmi-1–containing complexes are 
recruited to H3K27 trimethylation through the Pc and HP1 chro-
modomains (47). Consistent with these observations (24), our 
data revealed that the p16INK4 gene was co-occupied by PRC1 mem-
bers (Bmi-1 and Ring2), PRC2 members (EZH2 and SUZ12), and 
H3K27 trimethylation. Moreover, using the same ChIP products, 
several other PRC members including Ring 2, EZH2, and SUZ12 
as well as H3K27 trimethylation were found at the PTEN locus 
(Figure 4F). Taken together, our results show that PTEN is a direct 
target of PRC and is regulated by PRC in a similar manner to p16.
Ablation of PTEN expression restores the migratory/invasive pheno-
type and tumorigenicity of Bmi-1–silenced cancer cells. To analyze the 
functional correlation between PTEN and Bmi-1, we next tested 
whether knockdown of PTEN expression in Bmi-1–silenced can-
cer cells could reactivate PI3K/Akt/GSK-3β signaling and restore 
their migratory/invasive phenotype. As expected, silencing PTEN 
with both PTEN shRNAs in Bmi-1–silenced cells increased the 
expression of phosphorylated Akt and Snail (Figure 5A). More-
over, a Matrigel invasion chamber assay revealed that knockdown 
of PTEN partially restored the invasiveness of Bmi-1 shRNA/NPC 
cells. Partially restored motility and invasiveness of Bmi-1 knock-
down cells expressing PTEN shRNAs was confirmed by a wound-
healing assay and 3D Matrigel cultures (Supplemental Figure 6). 
To decipher the functional correlation between PTEN and Bmi-1 
in vivo, xenograft tumor experiments were performed. As shown 
in Figure 5C, in contrast to scrambled shRNA cells, Bmi-1 shRNA 
cells exhibited greatly reduced tumor growth, while PTEN knock-
down partially rescued the reduced tumorigenicity in Bmi-1–
silenced cells. These results suggest that PTEN could be a major 
negative regulator of Bmi-1–induced invasiveness/migration and 
tumorigenicity in cancer cells.
Bmi-1 expression negatively correlates with PTEN and E-cadherin in 
NPC. We further analyzed the expression levels of Bmi-1, Snail, 
PTEN, and E-cadherin in NPC cell lines and in clinical NPC sam-
ples. Western blot and real-time RT-PCR analyses revealed that 
Bmi-1 and Snail were markedly upregulated at both the protein 
and mRNA levels when compared with NPECs. Protein and mRNA 
expression levels for PTEN and E-cadherin were downregulated in 
NPC cell lines compared with normal cells (Figure 6, A and B). 
Furthermore, we measured expression of Bmi-1, Snail, PTEN, and 
E-cadherin in 2 normal nasopharyngeal epithelium tissues and 11 
clinical NPC samples using real-time RT-PCR. As shown in Fig-
ure 6C, the 11 NPC samples presented significantly higher levels 
of Bmi-1 (2- to 32-fold) and Snail (2- to 17-fold) as well as lower 
levels of PTEN (2- to 36-fold) and E-cadherin (2- to 14-fold) with 
respect to normal nasopharyngeal epithelium tissues. Statistical 
analysis revealed that Bmi-1 expression positively correlated with 
Snail (r = 0.882, P < 0.01) but negatively correlated with PTEN 
(r = –0.664, P = 0.026) and E-cadherin (r = –0.809, P < 0.01). Taken 
together, our results reveal an inverse relationship between high 
Bmi-1/Snail expression and low PTEN/E-cadherin expression in 
human cancers, further supporting a model of Bmi-1 association 
with the PTEN locus leading to transcriptional repression of PTEN 
expression, which results in activation of PI3K/Akt/GSK-3β/Snail 
signaling and E-cadherin downregulation (Figure 6D).
Discussion
NPC, one of the most common cancers in southern China, has the 
propensity to invade adjacent regions and metastasize to region-
al lymph nodes and distant organs (48). Efforts to elucidate the 
molecular mechanism underlying tumorigenicity, invasion, and 
metastasis of NPC are therefore warranted in order to develop 
novel treatments and a possible cure. In the current study, we 
have demonstrated that overexpression of Bmi-1 confers EMT to 
NPECs, and knockdown of Bmi-1 in NPC cell lines represses EMT 
and reduces invasiveness. We further demonstrated that Bmi-1 can 
directly target the tumor suppressor PTEN, activate the PI3K/AKT/
Snail pathway, and ultimately suppress E-cadherin expression.
Dysregulation of Bmi-1 alters cell proliferation, apoptosis, senes-
cence, and stem cell self-renewal and correlates with the invasive 
and metastatic phenotype of several human cancer types (14, 16, 
18, 20, 49, 50). However, the precise role and molecular mechanism 
underlying Bmi-1 involvement is ambiguous. EMT was originally 
identified as a critical factor in embryogenesis (51). During tumor 
progression, EMT is often involved in invasion and metastasis (52).
Figure 3
Bmi-1 induces PI3K/Akt activity and downregulates E-cadherin. (A) 
Cell extracts were analyzed by immunoblotting with antibodies against 
the indicated proteins. (B) Half-life analysis of the Snail protein. Cells 
were treated with 20 μM cycloheximide (CHX) for the indicated times 
and then analyzed by Western blotting. (C) The effect of Bmi-1 on the 
subcellular localization of Snail proteins (green) was examined under 
a fluorescent microscope. Scale bar: 80 μm. (D) E-cadherin mRNA 
expression was examined by real-time RT-PCR in triplicate. Error bars 
represent SEM (n = 3). Rel. exp., relative expression. (E) Luciferase 
activity under the control of the human E-cadherin promoter construct 
was measured in the indicated cells in triplicate. Error bars represent 
SEM (n = 3). **P < 0.01. (F) Repression of E-cadherin by Bmi-1 is 
dependent on Snail. (G) Binding of Bmi-1 to the E-cadherin promoter 
at different Snail expression levels was analyzed by ChIP. The results 
display the means ± SEM for 2 experiments performed in triplicate.
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Herein, we demonstrate that Bmi-1 induces EMT in NPECs and 
suppression of Bmi-1 in NPC cells reverses EMT. However, the typ-
ical EMT morphological change observed in NPECs only occurs in 
cells passaged several times after introduction of Bmi-1 (often after 
passage 5). Unlike the well-established cell lines, primary NPECs 
require several passages under selection before reaching a uniform 
phenotype after introduction of Bmi-1. To determine whether 
EMT is directly related to Bmi-1 expression, we introduced Bmi-1 
into MDCK cells, which have been widely used in EMT studies (34, 
53, 54). We observed the typical EMT phenotypes 1 week after ret-
roviral transduction of Bmi-1 (Supplemental Figures 1–3). Thus, 
Bmi-1 is sufficient to induce EMT in certain epithelial cells.
A recent report showed that Bmi-1 overexpression in MCF10A 
cells did not induce the EMT phenotype, but readily did so when 
co-expressed with RasG12V (55). Our data (Y. Feng, unpublished 
observations) are congruent 
with the prior observation; 
that is, Bmi-1 overexpres-
sion in primary mammary 
epithelial cells induces cell 
scattering and only mod-
erately elevates migration/
invasiveness without typi-
cal morphological changes 
in the monolayer culture. 
This cell type–specific func-
tion has been observed with 
other oncogenes, such as 
Ras, which alone induces 
only epithelial polarity 
modification in EpH4 cells 
but causes EMT in other 
epithelial cell lines (56). 
Overexpression of ILEI also 
induces cell type– or culture-
specific EMT or cell scat-
tering (57). Thus, Bmi-1– 
induced EMT may be a cell 
type–specific function.
EMT is a key developmen-
tal program that is often 
activated during embry-
onic development, tumor 
invasion, and metastasis. 
Evidence has shown that 
EMT can engender cells 
with properties of stem 
cells (58). Bmi-1 is required 
for proliferation of various 
differentiated cells and for 
self-renewal of stem cells 
(59–61). Thus, we exam-
ined whether Bmi-1 could 
induce a stem cell–like phe-
notype in NPC cell lines. We 
observed reduced ABCG2 
levels, decreased side popu-
lation cell proportions, and 
smaller and fewer spheres 
formed under nonadherent, 
serum-free culture conditions in Bmi-1–silenced cells compared 
with scrambled control cells (Supplemental Figure 7). These data 
suggest that a key role of Bmi-1 in EMT and tumor metastasis 
might be stem cell maintenance.
Although a significant correlation between Bmi-1 expression and 
local invasion of the primary tumor was observed in our previous 
study, we failed to show a significant correlation between Bmi-1 
expression and metastasis in NPC biopsies (20). This suggests that 
overexpression of Bmi-1 alone is not sufficient to induce metas-
tasis in NPC patients, and it may play a more important role in 
inducing local invasion of NPC. In addition, the limited sensitiv-
ity of immunohistochemistry used in the previous study may have 
encumbered the results. In the current study, we observed Bmi-1 
overexpression in all 11 NPC specimens by real-time PCR, although 
at differing levels. Thus, we believe it is important to perform 
Figure 4
Bmi-1 represses PTEN by binding to the PTEN promoter locus. (A) Top: Immunoblots showing expression of 
PTEN in the indicated cells. Bottom: Fold change of PTEN mRNA was analyzed by real-time RT-PCR. A rep-
resentative result from 3 different experiments is shown. Error bars indicate SEM (n = 3). (B) Cos-7 cells were 
transiently transfected with different amounts of pcDNA3/Bmi-1 and analyzed by Western blot. (C) Schematic 
representation of the PTEN promoter regions with or without binding affinity for Bmi-1. Precipitated DNA was 
amplified by PCR using primers specific for regions 1–10. The arrow indicates the transcriptional start site. 
ATG, translation start codon. (D) ChIP was performed by using anti–Bmi-1 antibody or anti-Flag antibody to 
identify Bmi-1 binding sites on the PTEN promoter in CNE2 cells. The p16 promoter was used as a positive 
control, and GAPDH was used as a negative control. (E) ChIP analysis of Bmi-1 binding efficiency in CNE2 
cells expressing the scrambled control shRNA or Bmi-1 shRNA #2. (F) Specific binding for H3K27 (H-3), Ring2, 
SUZ12, and EZH2 on PTEN and p16 loci was analyzed. Enriched chromatin was analyzed by the Bio-Profile 
computer-assisted imaging system. In D–F, bar graphs show the means ± SEM performed in triplicate.
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another clinical study with a larger cohort of samples to clearly 
demonstrate a correlation between Bmi-1 expression and the meta-
static status of NPC.
To our knowledge, this is the first study demonstrating an 
essential role for Bmi-1 in induction of EMT. Aside from Bmi-1, 
dysregulation of PcG genes is widespread in human tumors and 
correlates with the invasive or metastatic phenotype of certain 
carcinomas (6, 9, 10). A recent report described a novel role for an 
EZH2-associated methyltransferase complex in controlling actin 
polymerization in fibroblast cells (62). It suggested that EZH2 
might contribute to the metastatic development of cancer cells 
via regulation of actin-dependent cell adhesion and migration. In 
addition, EZH2 has been implicated in EMT induction by directly 
targeting ADRB2 and E-cadherin (37, 63). Taken together, EZH2 
may induce EMT and malignancy through multiple pathways. 
Thus, PcG proteins may play important roles in EMT induction.
An activated PI3K/Akt pathway is well documented for various 
human malignancies and sometimes correlates with an aggressive 
phenotype (reviewed in ref. 64). The PI3K/Akt pathway plays a cen-
tral role in EMT (26, 39–42). In this study, we observed hyperacti-
vation of PI3K/Akt in Bmi-1–induced EMT, which correlates with 
hyperphosphorylated GSK-3β, Snail stabilization, and E-cadherin 
downregulation. Snail triggers EMT by directly repressing E-cad-
herin transcription (30). Snail’s transcriptional activity is regulated 
by GSK-3β, which is negatively regulated by PI3K/Akt, MAPK, and 
Erk (44). Thus, the PI3K/Akt pathway seems to play a criteria role 
in Bmi-1–induced EMT. However, another crucial pathway regu-
lated by GSK-3β, the Wnt pathway, which is also involved in EMT 
and stem cell regulation, does not seem to be involved in EMT 
induced by Bmi-1 (Supplemental Figure 8).
Here we show, for what we believe is the first time, that the tumor 
suppressor PTEN is a downstream target of Bmi-1, which provides 
the molecular basis for activation of PI3K/Akt signaling in Bmi-1– 
overexpressing cells (38, 55), although there may be more Bmi-1 
targets that likely contribute to EMT and invasion/metastasis. 
PTEN is a dual lipid and protein phosphatase whose activity is lost 
by mutation, deletion, or promoter methylation silencing at a high 
frequency in many primary and metastatic human cancers (46, 65, 
66). PTEN functions as a negative regulator of the PI3K/Akt path-
way via dephosphorylation of PI(3,4,5)P3, ultimately participating 
Figure 5
Inhibition of PTEN expression by 
shRNA rescues migration/invasive-
ness and tumorigenicity in Bmi-1–
silenced cells. (A) Inhibiting PTEN 
expression by shRNAs results in 
activated Akt and rescue of Snail in 
Bmi-1–silenced CNE2 and HONE-1 
cells, as determined by Western blot-
ting. (B) The migration/invasiveness-
inducing properties of PTEN shRNAs 
or a scrambled control shRNA in 
Bmi-1 knockdown cell lines (CNE2 
and HONE-1) using a Matrigel-coat-
ed Boyden chamber as described 
in Figure 1D. Original magnification, 
×400. Error bars represent SEM. 
Lane 1, scramble control shRNA; 
lane 2, Bmi-1 shRNA #2; lane 3, 
Bmi-1 shRNA #2 and PTEN shRNA 
#1; lane 4, Bmi-1 shRNA #2 and 
PTEN shRNA #2. (C) Mice were 
injected subcutaneously with cells 
(105 cells/mouse). Tumor volumes 
were measured as described in Meth-
ods and plotted as the mean ± SEM. 
The left panel displays tumor growth 
in nude mice injected with the 3 
groups of cells (CNE2 scrambled 
control, CNE2 Bmi-1 shRNA #2, 
and CNE2 Bmi-1 shRNA #2/PTEN 
shRNA #2 cells).
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in regulation of the cell cycle, proliferation, apoptosis, cell adhesion, 
and EMT during embryonic development and cancer progression 
(42, 67). Our results provide multiple lines of evidence to support 
PTEN as a target of Bmi-1. First, there is an inverse relationship 
between Bmi-1 and PTEN expression in cells and human tumors. 
Second, inhibition of PTEN expression by shRNA in Bmi-1– 
repressed cells rescues PI3K/AKT activity and migration/invasive-
ness. Most importantly, Bmi-1 is able to bind the PTEN locus, which 
was co-occupied by PRC1/2 members as well as H3K27 trimeth-
ylation. In addition, the binding efficiency of Bmi-1 to the PTEN 
promoter is partially reduced after knockdown of Snail by a specific 
shRNA in NPC cells as determined by a ChIP assay (Supplemen-
tal Figure 9). Moreover, we demonstrate that Snail associates with 
the PTEN promoter and that binding efficiency can be reduced by 
silencing its expression (Supplemental Figure 10). Thus, our data 
indicate that binding of Bmi-1 to the PTEN promoter could be 
partially mediated by Snail. Similar results were published recently 
demonstrating that PRC2 could bind to the PTEN promoter in 
a Snail-dependent manner (45). In addition, Snail could repress 
PTEN expression by binding to the PTEN promoter during irradia-
tion (68). Our data indicate that there might be a positive feedback 
loop between suppression of PTEN and activation of Snail in NPC 
cells. Given that targets for the PRC2/3/4 member Suz12 are cell 
type–specific (69), it is unknown whether PTEN is a universal target 
for Bmi-1 across systems.
Interestingly, several independent genetic studies suggest that 
PTEN is a potential target of Bmi-1. First, both Bmi-1 transgen-
ic and heterozygous mutant PTEN (mPTEN3–5) mice show an 
increased incidence of T cell lymphoma (70, 71). Second, deletion 
of Arf or Ink4a-Arf only partially rescues defects in cerebellum 
development in Bmi-1–deficient mice (21, 72), while knockout of 
PTEN induces enhanced neural stem/progenitor cell proliferation 
and self-renewal (73). Finally, PTEN plays a role in the prevention 
of leukemogenesis in mice (20, 74), while overexpression of Bmi-1 
induces this process (59). However, demonstrating a direct link 
between Bmi-1 and PTEN in vivo may require generating double-
transgenic or double-knockout mice.
In summary, Bmi-1 plays an important role in the pathogenesis 
of NPC by inducing EMT partially by targeting the tumor sup-
pressor PTEN, thus activating the PI3K/Akt pathway. Uncovering 
a novel function and molecular mechanism for Bmi-1 overexpres-
sion in cancer provides important insight into understanding 
tumor progression and metastasis.
Methods
Cell culture, plasmids, and antibodies. Primary NPEC cultures and immortal-
ized NPECs induced by Bmi-1 were established as described previously (20) 
and grown in keratinocyte/serum-free medium (Invitrogen). All NPC cell 
lines were maintained in RPMI supplemented with 10% fetal bovine serum. 
Bmi-1 shRNA constructs were described previously (75). Other plasmids 
and antibodies are described in Supplemental Methods. Retroviruses were 
produced by transient transfection as described previously (76).
Tissue samples. Tissue specimens from 11 NPC tissues and 2 normal 
controls were obtained from the archives of the Department of Sample 
Resource of the Sun Yat-sen University Cancer Center. Patients’ consent 
and approval from the Sun Yat-sen University Cancer Center Institute 
Research Ethics Committee were obtained in order to use these clinical 
materials for research purposes.
Immunofluorescence analysis. Cells were stained for immunofluorescence 
on coverslips as described previously (20). Briefly, the cells were incubated 
with primary antibodies against E-cadherin, α-catenin, fibronectin, or 
vimentin and then incubated with rhodamine-conjugated or FITC-con-
jugated goat antibodies against rabbit or mouse IgG (Jackson Immuno-
Research Laboratories). The coverslips were counterstained with DAPI and 
imaged with a confocal laser-scanning microscope (Olympus FV1000). 
Data were processed with Adobe Photoshop 7.0 software.
Migration assay. See Supplemental Methods for details.
Wound-healing assay. See Supplemental Methods for details.
3D morphogenesis assay. Twenty-four–well dishes were coated with Growth 
Factor Reduced Matrigel (BD Biosciences) and covered with growth medi-
Figure 6
Endogenous expression of Bmi-1, Snail, 
PTEN, and E-cadherin in NPC cell lines 
and biopsies. (A and B) Endogenous 
expression of Bmi-1, Snail, PTEN, and 
E-cadherin in NPEC and NPC cancer cell 
lines were examined by Western blot (A) 
and real-time RT-PCR (B). mRNA expres-
sion levels for Bmi-1, Snail, PTEN, and 
E-cadherin were normalized with respect 
to GAPDH in real-time RT-PCR experi-
ments. Columns represent the mean from 
3 parallel experiments. (C) Real-time RT-
PCR data of Bmi-1, Snail, PTEN, and 
E-cadherin in 11 cases of NPC biopsies 
are presented as the fold change from the 
average expression levels in 2 normal tis-
sues. Columns are the average of 3 paral-
lel experiments. (D) Schematic represen-
tation of the major molecular mechanism 
of Bmi-1–induced EMT.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 119   Number 12   December 2009 3635
um supplemented with 2% Matrigel as previously described (2). Cells were 
trypsinized and seeded at a density of 104 cells/well, and medium was 
replaced with 2% Matrigel for 3 to 4 days. Microscopic images were cap-
tured at 2-day intervals for 2–3 weeks.
Anchorage-independent growth assays. Six-well plates were covered with a 
layer of 0.6% agar in medium supplemented with 20% fetal bovine serum. 
Cells were prepared in 0.3% agar and seeded in triplicate at 3 different dilu-
tions ranging from 1 × 103 to 5 × 105. The plates were incubated at 37°C in 
a humid atmosphere of 5% CO2 for 4 weeks. Each experiment was repeated 
at least 3 times. Colonies were photographed between 18 and 24 days at an 
original magnification of ×200 under phase contrast.
Experimental tumor and metastasis assay. Tumor formation and metasta-
sis of Bmi-1 shRNA cancer cells were determined by tail vein intravenous 
injection into 4- to 6-week-old Balb/C athymic nude mice (nu/nu) (see 
Supplemental Methods). The modified transplantation through subcuta-
neous injection is referred to in the report of Quintana et al. (77). Briefly, 
mice were subcutaneously injected with cells (105/mouse) mixed with 25% 
Matrigel (BD), and tumor sizes were measured every other day in order to 
calculate tumor volumes. All mice were sacrificed 3 weeks after injection.
Dual luciferase reporter assay. Luciferase activity was measured using 
the Dual-Luciferase Reporter Assay System (Promega). Cells at 50% con-
fluence in 12-well dishes were transfected using Fugene 6 (Roche). All 
experiments were performed in triplicate. Expression of firefly and renilla 
luciferases were analyzed 48 hours after transfection, according to the 
manufacturer’s instructions.
Real-time RT-PCR analysis. Real-time RT-PCR was carried out using an 
ABI PRISM 7500 Sequence Detection System (Applied Biosystems) (see 
Supplemental Methods). The primer sequences are provided in Supple-
mental Table 2.
ChIP assays. ChIP was performed as previously described (78). See Supple-
mental Methods for details.
Statistics. Statistical analyses were performed using SPSS 10.0. Differ-
ences among variables were assessed by χ2 analysis or 2-tailed Student’s 
t tests. Data were presented as the mean ± SEM unless otherwise indicated. 
A P value less than 0.05 was considered statistically significant.
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